The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. / Kobylecki, C.J.; Hansen, T.; Timm, S.; Wang, August Gabriel; Jakobsen, K.D.; Sørensen, Holger Jelling; Rasmussen, Henrik Barner; Werge, Thomas Mears; Kobylecki, Camilla J; Hansen, Thomas Folkmann; Timm, Sally; Wang, August; Jakobsen, Klaus D; Sørensen, Holger J; Rasmussen, Henrik B; Werge, Thomas.

I: Therapeutic Drug Monitoring, Bind 30, Nr. 3, 2008, s. 265-70.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Kobylecki, CJ, Hansen, T, Timm, S, Wang, AG, Jakobsen, KD, Sørensen, HJ, Rasmussen, HB, Werge, TM, Kobylecki, CJ, Hansen, TF, Timm, S, Wang, A, Jakobsen, KD, Sørensen, HJ, Rasmussen, HB & Werge, T 2008, 'The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study', Therapeutic Drug Monitoring, bind 30, nr. 3, s. 265-70. https://doi.org/10.1097/FTD.0b013e31817721d6

APA

Kobylecki, C. J., Hansen, T., Timm, S., Wang, A. G., Jakobsen, K. D., Sørensen, H. J., Rasmussen, H. B., Werge, T. M., Kobylecki, C. J., Hansen, T. F., Timm, S., Wang, A., Jakobsen, K. D., Sørensen, H. J., Rasmussen, H. B., & Werge, T. (2008). The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. Therapeutic Drug Monitoring, 30(3), 265-70. https://doi.org/10.1097/FTD.0b013e31817721d6

Vancouver

Kobylecki CJ, Hansen T, Timm S, Wang AG, Jakobsen KD, Sørensen HJ o.a. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. Therapeutic Drug Monitoring. 2008;30(3):265-70. https://doi.org/10.1097/FTD.0b013e31817721d6

Author

Kobylecki, C.J. ; Hansen, T. ; Timm, S. ; Wang, August Gabriel ; Jakobsen, K.D. ; Sørensen, Holger Jelling ; Rasmussen, Henrik Barner ; Werge, Thomas Mears ; Kobylecki, Camilla J ; Hansen, Thomas Folkmann ; Timm, Sally ; Wang, August ; Jakobsen, Klaus D ; Sørensen, Holger J ; Rasmussen, Henrik B ; Werge, Thomas. / The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study. I: Therapeutic Drug Monitoring. 2008 ; Bind 30, Nr. 3. s. 265-70.

Bibtex

@article{f416eb40f81411ddb219000ea68e967b,
title = "The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study",
abstract = "Suicidal behavior and substance abuse are frequent phenomena among patients with schizophrenia and may be attributable in part to antipsychotic treatment failure. Individuals who carry functional variants of the CYP2D6 and CYP2C19 genes, shown to cause altered drug metabolism of psychoactive drugs, are at risk of toxic accumulation or rapid elimination of these drugs, leading to treatment failure. We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia. Three hundred sixty-two patients with schizophrenia spectrum disorders (International Classification of Diseases, 10th Revision) were genotyped for functional CYP2D6 and CYP2C19 polymorphisms. Based on available medical records and clinical interviews, their suicidal behavior and substance abuse disorder were evaluated. No significant associations between the CYP2D6 and CYP2C19 genotypes and suicidal behavior or substance abuse disorder were noted, and we conclude that cytochrome P450 genotyping in its present form is clinically irrelevant with respect to these phenomena.",
author = "C.J. Kobylecki and T. Hansen and S. Timm and Wang, {August Gabriel} and K.D. Jakobsen and S{\o}rensen, {Holger Jelling} and Rasmussen, {Henrik Barner} and Werge, {Thomas Mears} and Kobylecki, {Camilla J} and Hansen, {Thomas Folkmann} and Sally Timm and August Wang and Jakobsen, {Klaus D} and S{\o}rensen, {Holger J} and Rasmussen, {Henrik B} and Thomas Werge",
note = "Keywords: Adult; Analysis of Variance; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Odds Ratio; Patient Compliance; Phenotype; Polymorphism, Genetic; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders; Suicide; Treatment Outcome",
year = "2008",
doi = "http://dx.doi.org/10.1097/FTD.0b013e31817721d6",
language = "English",
volume = "30",
pages = "265--70",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams & Wilkins",
number = "3",

}

RIS

TY - JOUR

T1 - The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study

AU - Kobylecki, C.J.

AU - Hansen, T.

AU - Timm, S.

AU - Wang, August Gabriel

AU - Jakobsen, K.D.

AU - Sørensen, Holger Jelling

AU - Rasmussen, Henrik Barner

AU - Werge, Thomas Mears

AU - Kobylecki, Camilla J

AU - Hansen, Thomas Folkmann

AU - Timm, Sally

AU - Wang, August

AU - Jakobsen, Klaus D

AU - Sørensen, Holger J

AU - Rasmussen, Henrik B

AU - Werge, Thomas

N1 - Keywords: Adult; Analysis of Variance; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Odds Ratio; Patient Compliance; Phenotype; Polymorphism, Genetic; Retrospective Studies; Schizophrenia; Schizophrenic Psychology; Substance-Related Disorders; Suicide; Treatment Outcome

PY - 2008

Y1 - 2008

N2 - Suicidal behavior and substance abuse are frequent phenomena among patients with schizophrenia and may be attributable in part to antipsychotic treatment failure. Individuals who carry functional variants of the CYP2D6 and CYP2C19 genes, shown to cause altered drug metabolism of psychoactive drugs, are at risk of toxic accumulation or rapid elimination of these drugs, leading to treatment failure. We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia. Three hundred sixty-two patients with schizophrenia spectrum disorders (International Classification of Diseases, 10th Revision) were genotyped for functional CYP2D6 and CYP2C19 polymorphisms. Based on available medical records and clinical interviews, their suicidal behavior and substance abuse disorder were evaluated. No significant associations between the CYP2D6 and CYP2C19 genotypes and suicidal behavior or substance abuse disorder were noted, and we conclude that cytochrome P450 genotyping in its present form is clinically irrelevant with respect to these phenomena.

AB - Suicidal behavior and substance abuse are frequent phenomena among patients with schizophrenia and may be attributable in part to antipsychotic treatment failure. Individuals who carry functional variants of the CYP2D6 and CYP2C19 genes, shown to cause altered drug metabolism of psychoactive drugs, are at risk of toxic accumulation or rapid elimination of these drugs, leading to treatment failure. We tested whether substance abuse disorder and suicidal behavior were associated with the CYP2D6 and CYP2C19 genotypes among patients with schizophrenia. Three hundred sixty-two patients with schizophrenia spectrum disorders (International Classification of Diseases, 10th Revision) were genotyped for functional CYP2D6 and CYP2C19 polymorphisms. Based on available medical records and clinical interviews, their suicidal behavior and substance abuse disorder were evaluated. No significant associations between the CYP2D6 and CYP2C19 genotypes and suicidal behavior or substance abuse disorder were noted, and we conclude that cytochrome P450 genotyping in its present form is clinically irrelevant with respect to these phenomena.

U2 - http://dx.doi.org/10.1097/FTD.0b013e31817721d6

DO - http://dx.doi.org/10.1097/FTD.0b013e31817721d6

M3 - Journal article

VL - 30

SP - 265

EP - 270

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -

ID: 10449513